콘텐츠로 건너뛰기
Merck
모든 사진(2)

주요 문서

SML3804

Sigma-Aldrich

PMX205 trifluoroacetate

≥98% (HPLC)

동의어(들):

Hydrocinnamate (HC)-[OP(D-Cha)WR] trifluoroacetate, (5→1)-lactam-N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine trifluoroacetate, HC-[OP(D-Cha)WR] trifluoroacetate, HC-[Orn-Pro-dCha-Trp-Arg] trifluoroacetate, Hydrocinnamate-(L-ornithine-proline-D-cyclohexylalanine-tryptophan-arginine) trifluoroacetate;, Hydrocinnamate-(OPdChaWR) trifluoroacetate, Hydrocinnamate-[OP(D-Cha)WR] trifluoroacetate, PMX 205 trifluoroacetate, PMX-205 trifluoroacetate, c[Arg-Trp-D-Cha-Pro-Orn]-Hca trifluoroacetat

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C45H62N10O6 · xC2HF3O2
Molecular Weight:
839.04 (free base basis)
MDL number:
UNSPSC 코드:
51111800
UNSPSC 코드:
12352200
NACRES:
NA.21

Quality Level

분석

≥98% (HPLC)

양식

(Powder or Lyophilized powder or film)

저장 조건

desiccated

색상

white to off-white

저장 온도

-10 to -25°C

SMILES string

N21[C@@H](CCC2)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC[C@@H](C1=O)NC(=O)CCc6ccccc6)CCCNC(=N)N)Cc4c5c([nH]c4)cccc5)CC3CCCCC3

InChI

1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-

InChI key

VATFHFJULBPYLM-ILOBPARPSA-N

생화학적/생리학적 작용

Blood-brain barrier-permeable and orally active C5aR1 antagonist with 10- to 30-times higher in vivo efficacy than PMX53 in a rat colitis model.
PMX205 is a blood-brain barrier (BBB)-permeable and orally active cyclic hexapeptide that acts as a high-affinity and potent antagonist against complement C5a receptor C5aR1. Unlike its structural analog PMX53, PMX205 is resistant to intestinal metabolism and shows 10-30-times higher in vivo efficacy when administered orally (mortality rate = 1/9 with 0.1 mg/kg/day PMX205 vs. 2/10 with 1 mg/kg/day PMX53 in a rat colitis model) despite similar in vitro potency (PMX205/PMX53 pIC50 = 6.50/6.38 against 50 pM C5a by competitive binding, 9.03/8.24 against C5a-induced human PMN MPO release). PMX205 shows in vivo efficacy in animal models of AD (3-6 mg/kg/day p.o., mice), ALS (1 mg/kg/day p.o., rats), and HD (10 mg/kg/day p.o., rats).

주의사항

Hygroscopic

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration
Faseb Journal, 20(9), 1407-1417 (2006)
Trent M Woodruff et al.
The Journal of pharmacology and experimental therapeutics, 314(2), 811-817 (2005-05-10)
We have previously shown that complement factor 5a (C5a) plays a role in the pathogenesis of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats by using the selective, orally active C5a antagonist AcF-[OP(d-Cha)WR]. This study tested the efficacy and potency of
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease
Journal of immunology (Baltimore, Md. : 1950), 183(2), 1375-1383 (2009)

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.